Navigation Links
Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
Date:4/21/2008

VANCOUVER, April 21 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has elected to suspend enrolment in its U.S. and EU human clinical trials for its Vascular Wrap product candidate in patients undergoing surgery for hemodialysis access, pending a safety review to evaluate an imbalance of infections that have been observed between the two study groups. The U.S. and EU trials each consist of two study groups; (1) patients who received the graft/Vascular Wrap combination; and, (2) patients who received the graft alone.

At the onset of this study Angiotech established an independent Data Safety Monitoring Board (DSMB) in the U.S. to monitor any unexpected risks or safety issues. Angiotech recently submitted a safety summary of adverse events from the U.S. clinical trial to the DSMB, based upon having reached the 25% enrolment threshold in the U.S. clinical trial. Subsequent to that submission, Angiotech received a communication from the DSMB that one of the study groups had a greater incidence of implant site infection in comparison with the other study group. Angiotech is blinded to the groups and not currently aware of whether the increased rate of infection is in the patient group that received the graft/Vascular Wrap combination or in the patient group that received the graft alone. As a result of these observations, Angiotech has elected to notify physicians to suspend further enrolment in the trials, pending a full review of the potential cause of the implant site infections.

"We regard patient safety as the paramount obligation of any company in our industry, and upon further adjudication of the clinic
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
2. Angiotechs novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
3. Angiotech announces director resignation
4. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
5. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
6. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
7. Angiotech to participate in Lehman Brothers Healthcare Conference
8. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
9. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
10. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
11. Angiotech announces results for the fourth quarter ended December 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the six months ended June ... in Canadian dollars and presented under International Financial ... Highlights , Announced top-line results related ... endpoint for subjects enrolled in the Phase 2 ...
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... LAFAYETTE, Ind. A new research platform ... properties of tiny structures undergoing stress and ... to improve designs for microelectronics and batteries., ... reveals information about how heating and the ... mechanical properties. Researchers have discussed the merits ...
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... 10 Corthera Inc. today,announced that an interim ... portion of a Phase II/III multicenter, randomized, double-blind,international ... the,company,s investigational drug for treatment of acute heart ... presented by John R. Teerlink, M.D.,Professor of Medicine, ...
... 3SBio Inc. (Nasdaq:,SSRX), a leading biotechnology company focused ... in China,today announced that it has filed with ... approval of NuLeusin for the treatment of late,stage ... expected to,be the only treatment of this kind ...
... today,announced financial results for the second quarter ended September ... quarter, representing an,increase of 27.1% from 100.9 billion yen ... results of PENTAX included in the scope of,consolidation during ... billion yen, a 23.2% decrease compared with,26.8 billion yen ...
Cached Biology Technology:Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure 2Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure 33SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4Hoya Announces Second Quarter and First Half Financial Results for FY2008 2
(Date:9/1/2014)... the Nomenclature Section of the XVIII International Botanical Congress ... meeting is held every six years and it is ... naming algae, fungi and plants get together to debate ... they study. This is the primary product of the ... and plants, which was published in 2012. The other ...
(Date:8/31/2014)... go after each other. But when viruses invade bacteria, ... Sometimes viruses actually carry helpful genes that a bacterium ... attack its own hosts. , Scientists have assumed the ... anything it recognized as invading viral genes. However, new ... variety of the bacterial immune system known as the ...
(Date:8/29/2014)... at UC Davis have made some surprising discoveries ... Studying simian immunodeficiency virus (SIV), the team found ... cells are early responders to viral invasion and ... a cytokine called interleukin-1 beta (IL-1β). , ... causes breakdown of the gut epithelium that provides ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3The early cost of HIV 2
... -- Zeroing in on the early cell mutations that enable a ... a personalized therapy to stop it. Scientists were able to use ... order in which these abnormalities form to analyze the pattern of ... findings, which are published in the July edition of Cancer ...
... 29, 2011 BD Biosciences, a segment of ... availability of BD Recharge™, a chemically defined (CD) ... offers productivity comparable to yeast-based peptones. ... for biopharmaceutical cell culture," said Robert Hallenbeck, Vice ...
... uncovered half-a-billion-year-old fossils demonstrating that primitive animals had excellent vision. ... South Australian Museum and the University of Adelaide ... from a recently swatted fly. This discovery will be ... Nature . The lead author is ...
Cached Biology News:Scientists develop method to determine order of mutations that lead to cancer 2BD Biosciences Introduces Chemically Defined Cell Culture Media Supplement that Increases Biopharmaceutical Protein Production 2New fossils demonstrate that powerful eyes evolved in a twinkling 2
... The EZ DNA Methylation Kit uses a ... for DNA methylation analysis. The kit is ... takes place between cytosine and sodium bisulfite ... EZ DNA Methylation Kits innovative in-column desulphonation ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
The Odyssey Infrared Imaging System is a complete family of products that includes the Odyssey Imager, IRDye labeling reagents and Odyssey software for scan control and data analysis....
... EIA Principle: The ... LTE4 are products of arachidonic ... glutathione-S-transferase. In the past, they ... Substances of Anaphylaxis (SRS-A)". They ...
Biology Products: